Lung Cancer Clinical Trial

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Summary

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

View Full Description

Full Description

This study will consist of two treatment arms (Groups A and B).

Participants will be randomised in a 1:1 ratio to one of the two treatment groups:

Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously.
Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically documented NSCLC that is locally advanced or metastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.
Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.
Documented radiological PD whilst on or after receiving the most recent treatment regimen.
Eligible for second- or third-line therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC either separately or in combination.
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0 or 1.
Adequate organ function and marrow reserve
Minimum life expectancy of 12 weeks.
Body weight > 30 kg and no cancer-associated cachexia.
Negative pregnancy test (serum test) for women of childbearing potential (WOCBP).

Exclusion Criteria:

Participant with mixed SCLC and NSCLC histology.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention.
Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.
Active or prior documented autoimmune or inflammatory disorders.
Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.

Participants:

Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.
All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.
Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.
Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

580

Study ID:

NCT05450692

Recruitment Status:

Recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 80 Locations for this study

See Locations Near You

Research Site
Chandler Arizona, 85224, United States
Research Site
Los Angeles California, 90017, United States
Research Site
Atlanta Georgia, 30318, United States
Research Site
Baltimore Maryland, 21231, United States
Research Site
Canton Ohio, 44718, United States
Research Site
Allentown Pennsylvania, 18103, United States
Research Site
Houston Texas, 77090, United States
Research Site
Lacey Washington, 98503, United States
Research Site
Caba , C1280, Argentina
Research Site
Cordoba , 5000, Argentina
Research Site
Pergamino , B2700, Argentina
Research Site
Viedma , R8500, Argentina
Research Site
Elizabeth Vale , 5112, Australia
Research Site
South Brisbane , 4101, Australia
Research Site
Wendouree , 3355, Australia
Research Site
Wollongong , 2500, Australia
Research Site
Charleroi , 6000, Belgium
Research Site
Gent , 9000, Belgium
Research Site
Libramont-Chevigny , 6800, Belgium
Research Site
Roeselare , 8800, Belgium
Research Site
Fortaleza , 60810, Brazil
Research Site
Porto Alegre , 90110, Brazil
Research Site
Porto Alegre , 90610, Brazil
Research Site
Salvador , 40170, Brazil
Research Site
Sao Paulo , 01246, Brazil
Research Site
São Paulo , 04014, Brazil
Research Site
Vancouver British Columbia, VSZ 4, Canada
Research Site
Newmarket Ontario, L3Y 2, Canada
Research Site
Chicoutimi Quebec, G7H 7, Canada
Research Site
Montreal Quebec, H2L 4, Canada
Research Site
Montreal Quebec, H3G 1, Canada
Research Site
Rimouski Quebec, G5L 5, Canada
Research Site
Baoding , 07100, China
Research Site
Beijing , 10002, China
Research Site
Beijing , 10004, China
Research Site
Changsha , 41000, China
Research Site
Changsha , 41001, China
Research Site
Chengdu , 61004, China
Research Site
Guangzhou , 51008, China
Research Site
Hefei , 23000, China
Research Site
Jinan , 25001, China
Research Site
Nanchang , 33000, China
Research Site
Nanjing , 21002, China
Research Site
Qingdao , 26607, China
Research Site
Taiyuan , 03000, China
Research Site
Tianjin , 30005, China
Research Site
Wuhan , 43000, China
Research Site
Wuhan , 43002, China
Research Site
Wuhan , 43007, China
Research Site
Yantai , 26400, China
Research Site
Zhanjiang , 52400, China
Research Site
King's Park , 15000, Hong Kong
Research Site
Tun Mun , , Hong Kong
Research Site
Budapest , 1121, Hungary
Research Site
Székesfehérvár , 8000, Hungary
Research Site
Törökbálint , 2045, Hungary
Research Site
Zalaegerszeg , 8900, Hungary
Research Site
Aviano , 33081, Italy
Research Site
Catania , 95123, Italy
Research Site
Livorno , 57124, Italy
Research Site
Meldola , 47014, Italy
Research Site
Milano , 20133, Italy
Research Site
Monza , 20900, Italy
Research Site
Napoli , 80131, Italy
Research Site
Padova , 35128, Italy
Research Site
Parma , 43126, Italy
Research Site
Rozzano , 20089, Italy
Research Site
Verona , 37126, Italy
Research Site
Cheongju-si , 28644, Korea, Republic of
Research Site
Seoul , 03181, Korea, Republic of
Research Site
Seoul , 03722, Korea, Republic of
Research Site
Seoul , 07061, Korea, Republic of
Research Site
Seoul , 13620, Korea, Republic of
Research Site
Seoul , 138-7, Korea, Republic of
Research Site
Suwon , 16247, Korea, Republic of
Research Site
Gdansk , 80-95, Poland
Research Site
Gdańsk , 80-21, Poland
Research Site
Krakow , 30-51, Poland
Research Site
Poznan , 60-69, Poland
Research Site
Skórzewo , 60-18, Poland
Research Site
Taoyuan City , 333, Taiwan

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

580

Study ID:

NCT05450692

Recruitment Status:

Recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.